Shares of Guardant Health, Inc. (NASDAQ:GH – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the nineteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $89.00.
Several equity analysts recently weighed in on the stock. BTIG Research cut their price objective on shares of Guardant Health from $80.00 to $60.00 in a research report on Friday, December 16th. Cowen cut their price objective on shares of Guardant Health from $83.00 to $70.00 in a research report on Friday, December 16th. Credit Suisse Group cut their price objective on shares of Guardant Health from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, November 4th. Citigroup dropped their price target on shares of Guardant Health from $80.00 to $60.00 in a research report on Friday, December 16th. Finally, Stephens dropped their price target on shares of Guardant Health from $99.00 to $90.00 and set an “overweight” rating on the stock in a research report on Monday, November 7th.
Insider Transactions at Guardant Health
In other Guardant Health news, insider Kumud Kalia sold 3,125 shares of Guardant Health stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $51.87, for a total transaction of $162,093.75. Following the sale, the insider now owns 20,135 shares in the company, valued at $1,044,402.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this link. 5.90% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Guardant Health
A number of institutional investors have recently bought and sold shares of GH. Xponance Inc. boosted its stake in shares of Guardant Health by 2.4% in the 3rd quarter. Xponance Inc. now owns 11,639 shares of the company’s stock valued at $627,000 after purchasing an additional 269 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of Guardant Health by 33.2% in the 2nd quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock valued at $44,000 after purchasing an additional 271 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Guardant Health by 4.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 6,120 shares of the company’s stock valued at $246,000 after purchasing an additional 286 shares in the last quarter. Manchester Capital Management LLC boosted its stake in shares of Guardant Health by 43.0% in the 3rd quarter. Manchester Capital Management LLC now owns 965 shares of the company’s stock valued at $52,000 after purchasing an additional 290 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its stake in shares of Guardant Health by 2.1% in the 3rd quarter. Baird Financial Group Inc. now owns 14,580 shares of the company’s stock valued at $785,000 after purchasing an additional 296 shares in the last quarter. Institutional investors and hedge funds own 90.43% of the company’s stock.
Guardant Health Price Performance
Shares of GH opened at $28.40 on Friday. The firm has a market cap of $2.91 billion, a PE ratio of -4.79 and a beta of 0.86. The firm’s 50 day moving average price is $33.17 and its 200 day moving average price is $44.84. The company has a debt-to-equity ratio of 6.82, a quick ratio of 6.10 and a current ratio of 6.46. Guardant Health has a twelve month low of $24.63 and a twelve month high of $78.34.
About Guardant Health
(Get Rating)
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.
Featured Articles
Receive News & Ratings for Guardant Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Guardant Health and related companies with MarketBeat.com’s FREE daily email newsletter.